Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Risperdal Consta Clear all
Completed Phase 4 Interventional Results available

Clozapine for Cannabis Use in Schizophrenia

NCT01639872
View directory record Official record
Conditions
Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
Interventions
Clozapine, Risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Garden Grove, California • Oakland, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Antipsychotic Discontinuation in Alzheimer's Disease

NCT00417482
View directory record Official record
Conditions
Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
Interventions
risperidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Improving Work Outcome in People With Recent-onset Schizophrenia

NCT00203788
View directory record Official record
Conditions
Schizophrenia
Interventions
Individual Placement and Support, Workplace Fundamentals Module, Brokered Vocational Rehabilitation, Oral risperidone, Skills training group
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

A Study of Risperidone Monotherapy in Bipolar Anxiety

NCT00167479
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
risperidone (Risperdal)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Tampa, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 3 Interventional

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

NCT00148083
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal Consta (drug), Social Skills Training
Drug · Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • White Plains, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 30, 2026, 4:05 PM EDT
Withdrawn Phase 4 Interventional

Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment

NCT00178854
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Risperidone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

First Episode Schizophrenia and Cannabis-Related Disorder Study

NCT00573287
View directory record Official record
Conditions
Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
Interventions
clozapine, risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
17 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Concord, New Hampshire • Lebanon, New Hampshire • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

NCT01086748
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Placebo, LY2140023
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Escondido, California • Garden Grove, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Not applicable Interventional

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

NCT00227123
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
Interventions
quetiapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Metabolic Effects of Antipsychotics in Children

NCT00205699
View directory record Official record
Conditions
Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
Interventions
risperidone, olanzapine, aripiprazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 30, 2026, 4:05 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

NCT00435370
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia
Interventions
Tropisetron, Placebo, Risperidone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

NCT03978832
View directory record Official record
Conditions
Schizophrenia
Interventions
PERSERIS, Risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 30, 2026, 4:05 PM EDT
Terminated Phase 4 Interventional

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCT00314613
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic/Risperidone Consta
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 4:05 PM EDT
Recruiting Phase 4 Interventional

CLOZAPINE Response in Biotype-1

NCT04580134
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Not applicable Interventional Results available

Glucose and Lipid Metabolism on Antipsychotic Medication

NCT00515723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
risperidone, olanzapine, quetiapine, ziprasidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 30, 2026, 4:05 PM EDT
Completed No phase listed Observational

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

NCT01181960
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Risperidone long acting injectable - New Starts, Risperidone long acting injectable - Continuous Users, Paliperidone Palmitate -New and Continuous Users, Other Antipsychotics - New Starts
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Bullhead City, Arizona • Colton, California • Imperial, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 30, 2026, 4:05 PM EDT
Not listed Phase 4 Interventional

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

NCT00937261
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Paliperidone
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
Interventions
Risperidone, Other atypical antipsychotic drugs
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
8 Years to 16 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone.

NCT05179525
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional

Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

NCT00215579
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Depot Risperidone Microsphere (Consta)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Butner, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 30, 2026, 4:05 PM EDT
Withdrawn Not applicable Interventional

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

NCT01770600
View directory record Official record
Conditions
Impulsivity, Active Suicidal Ideation, Depression
Interventions
placebo, Riperidone
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 30, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 30, 2026, 4:05 PM EDT